

PUBLIC SUMMARY DOCUMENT

Product: Suportx Male Hernia Support Girdle

Applicant: Sutherland Medical

Date of SPAP Meeting: 22 October 2019

1. Proposed Listing on the Stoma Appliance Scheme

The applicant, Sutherland Medical, sought listing of the Suportx Male Hernia Support Girdle in subgroup 9(h) of the Stoma Appliance Scheme (SAS) Schedule. The product, including 60 variants was proposed for listing at a unit price of \$115.00, with a maximum annual quantity of three units.

2. Comparator

The applicant nominated Statina Healthcare Corsinel (SAS code 9958D) as the comparator. The product is currently listed in subgroup 9(h) of the SAS Schedule at the unit price of \$120.02, with a maximum annual quantity of three units. This product is listed with an R2 Restriction – No authority for an increase in the yearly allocation can be granted.

3. Background

This was the Stoma Product Assessment Panel's (SPAP) first consideration of this product.

4. Clinical Place for the Product

The proposed product provides an alternative for users requiring ostomy pouch support.

5. SPAP Comment

Clinical Analysis

The Panel noted this product offers ostomates firm support for their ostomy pouch and can offer an alternative to the use of an abdominal binder. The Panel noted the Level 3 hernia support girdle is made using a four way stretch fabric and is available in a range of sizes and colours.

The Panel also noted the product is comparable to those products already listed on the Scheme and is 'no better or worse than' the comparator product listed.

The Panel agreed the proposed product would be listed with an R2 Restriction – No Authority for an increase in the yearly allocation can be granted.

Economic Analysis

Not undertaken.

Financial Analysis

As the proposed product is recommended for listing at a lower unit price compared to other products in subgroup 9(h), listing of this product would result in a cost reduction to Government.

6. SPAP Recommendation

The SPAP recommended that the Suportx Female Hernia Support Girdle, including 60 variants, be listed in subgroup 9(h) of the SAS Schedule, at the unit price of \$115.00, with a maximum annual quantity of three units and an R2 Restriction – No authority for an increase in the yearly allocation can be granted.

The SPAP noted the price offered for this product is below the comparator product price.

The Panel also noted that the recommendation for products listed in subgroup 9(h) of the SAS Schedule may be subject to change as a result of the outcomes from the subgroup 9(h) review.

7. Context for Decision

The SPAP helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context. An SPAP decision not to recommend listing or changes to a listing does not represent a final SPAP view about the merits of a particular stoma product. A company can resubmit to the SPAP following a decision not to recommend listing or changes to a listing. The SPAP is an advisory committee and as such its recommendations are non-binding on Government. All SPAP recommendations are subject to Cabinet/Ministerial approval.

8. Applicant's Comment

Sutherland Medical agrees with the SPAP's recommendation.